Modality
Nanobody
MOA
PD-L1i
Target
AuroraA
Pathway
Notch
NASH
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
Dec 2019
→ Jan 2030
Phase 1Current
NCT05416490
243 pts·NASH
2023-07→2030-01·Recruiting
NCT06867355
112 pts·NASH
2019-12→2025-02·Recruiting
355 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-021.2y agoInterim· NASH
2030-01-173.8y awayInterim· NASH
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Recruit…
P1
Recruit…
Catalysts
Interim
2025-02-02 · 1.2y ago
NASH
Interim
2030-01-17 · 3.8y away
NASH
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05416490 | Phase 1 | NASH | Recruiting | 243 | Biomarker |
| NCT06867355 | Phase 1 | NASH | Recruiting | 112 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| ARG-6988 | Argenx | Preclinical | AuroraA |